NXTM has changed there accounting practice January 1st from GAAP to ASU (accounting standard update) this I gather is to capture revenues from international equiptment sales upon delivery to distributors as opposed to fractional payments to NXTM strung out over a five year period. Sounds like there product is well established in there distributorships and we may be off and running. I expect to see this stock move up. Anybody see different.
The Fresenius 2008K @ home machine is based on the old 2008H&K Machines. Too complicated for the average dialysis patient. One look at this dialysis machine and I said NxStage does not have a problem competing with this. If NxStage drops to $15.00 I will buy another 1000 shares.
Have you seen the baby K? You got to be kidding. The next best thing for competition is the Aksys machine that Baxter bought, but don't know where this is in development. Baby K way to cumbersome, need water tx system, special wiring, pain in the butt.
I would think the news of FMS coming out with an in home dialysis would just urge larger companies that want to be in this market to want to acquire this (NXTM) company so they don't have to develope a competitor and re-invent the wheel.
Well, I am not sure everything you said makes sense since ASU's are created by the FASB and are based on GAAP, not international standards. However, that being said, I don't see any issue with NxStage following a more progressive ASU standard that allows them to capture more revenue in the short term. The fact that it may be closer to international standards is a bonus. The entire US GAAP system is slated to merge with international standards within the next four years under IFRS. Smart business is smart business. They are doing well and pretty much exactly as they expected. Go NxStage...